Unknown

Dataset Information

0

Niclosamide, an antihelmintic drug, enhances efficacy of PD-1/PD-L1 immune checkpoint blockade in non-small cell lung cancer.


ABSTRACT: BACKGROUND:PD-1/PD-L1 blockade has received approval for clinical application due to its encouraging benefit with improving prognosis in selected populations. Unfortunately, the response to immunotherapy for many patients remains unsatisfactory. It remains a great challenge to generate potential combinations that will outperform single agents alone with regard to anti-tumor activity. METHODS:Using NSCLC cell lines and mouse models, we explored the effects of combined niclosamide and PD-L1 blockade on tumor growth and T cell function. Furthermore, we investigated the relationship between PD-L1 and p-STAT3 expression in tumor samples from patients with NSCLC using IHC, as well as their relationship to patient survival. RESULTS:In vitro, niclosamide, an antihelmintic drug, enhanced the cancer cell lysis mediated by T cells in the presence of PD-L1 blockade. Accordingly, mice treated with niclosamide and PD-L1 antibody showed significant delay in tumor growth and increased survival which were associated with the increase of tumor infiltrating T cells and granzyme B release. Importantly, we found niclosamide could decrease the expression of PD-L1 in both a concentration- and time-dependent manner in NSCLC cells, which was linked to the blockage of p-STAT3 binding to the promoter of PD-L1. CONCLUSIONS:An enhancement of PD-L1 antibody by niclosamide was observed in inhibition of NSCLC growth in vitro and in vivo, which was involved in blockage of p-STAT3 binding to promoter of PD-L1 and finally downregulation of PD-L1 expression. These encourage the combination therapy of niclosamide and PD-1/PD-L1 blockade to be further studied in clinic.

SUBMITTER: Luo F 

PROVIDER: S-EPMC6739982 | biostudies-literature | 2019 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Niclosamide, an antihelmintic drug, enhances efficacy of PD-1/PD-L1 immune checkpoint blockade in non-small cell lung cancer.

Luo Fan F   Luo Min M   Rong Qi-Xiang QX   Zhang Hong H   Chen Zhen Z   Wang Fang F   Zhao Hong-Yun HY   Fu Li-Wu LW  

Journal for immunotherapy of cancer 20190911 1


<h4>Background</h4>PD-1/PD-L1 blockade has received approval for clinical application due to its encouraging benefit with improving prognosis in selected populations. Unfortunately, the response to immunotherapy for many patients remains unsatisfactory. It remains a great challenge to generate potential combinations that will outperform single agents alone with regard to anti-tumor activity.<h4>Methods</h4>Using NSCLC cell lines and mouse models, we explored the effects of combined niclosamide a  ...[more]

Similar Datasets

| S-EPMC6209395 | biostudies-literature
| S-EPMC4497957 | biostudies-literature
| S-EPMC5290437 | biostudies-literature
| S-EPMC9980712 | biostudies-literature
| S-EPMC7878408 | biostudies-literature
| S-EPMC6136863 | biostudies-other
| S-EPMC6205063 | biostudies-literature
| S-EPMC7781712 | biostudies-literature
| S-EPMC4429737 | biostudies-literature
| S-EPMC5341541 | biostudies-literature